Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diabetes product integration

This article was originally published in The Gray Sheet

Executive Summary

Roche's goal of creating an artificial pancreas "sometime between 2008 and 2010" trumps short-term objective of being first to market with a continuous blood glucose measuring device, though such a monitor will begin clinical testing this year, von Prondzynski suggests Feb. 4. "Will we beat the competitors? Probably not. I don't think first to market is the most important thing here. I think what matters is quality," he offers. Roche forecasts successful FDA re-inspection of Disetronic unit's Burgdorf, Switzerland facility for late Q2, enabling firm to launch Minitron next-gen insulin pump in the U.S. by Q4. Roche will "take advantage of this year" as competitors Abbott and TheraSense will be pre-occupied with aligning their manufacturing capacity, von Prondzynski tells "The Gray Sheet"...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT019705

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel